Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01592773 · ClinicalTrials.gov registry record · Phase 2
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
A Phase 2 study, sponsored by Forest Laboratories.
- Terminated
- Registry status
- Phase 2
- Development phase
- 747
- Enrollment target
NCT01592773 is a Phase 2 study that was terminated before completion, run by Forest Laboratories. The registered enrollment target is 747 participants.
The verdict
NCT01592773, a Phase 2 study, was terminated before completion, sponsored by Forest Laboratories.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 747 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the long-term safety and tolerability of memantine in the treatment of pediatric patients with autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS).
Interventions
- DRUG Memantine Hydrochloride (HCl)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 747 participants |
| Start Date | 2012-10 |
| Est. Completion | 2014-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01592773
The ClinicalTrials.gov registry entry for NCT01592773 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 747 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Memantine Hydrochloride (HCl) is the first listed.
NCT01592773 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01592773 about?
NCT01592773 is a clinical study titled "Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)". The objective of this study is to evaluate the long-term safety and tolerability of memantine in the treatment of pediatric patients with autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS).
What is the current status of trial NCT01592773?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 747 participants. The study started on 2012-10. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01592773?
The interventions under investigation include: Memantine Hydrochloride (HCl) (DRUG).
Who is sponsoring clinical trial NCT01592773?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.